Seroprevalence of SARS-CoV-2 IgG in people with cystic fibrosis
Description
CONCLUSION: To our knowledge, this is the first report on the seroprevalence and longevity of SARS-CoV-2 IgG to 1 year in adults with CF after the widespread availability of SARS-CoV-2 vaccinations. These data show that pwCF respond to the COVID
